Jubilant Ingrevia Q2 Profit Surges 60% as Firm Enters Electronics Sector

Revenue hits Rs 1,394 crore, Net Profit touches Rs 111 crore.
Reader Takeaway: Strong core chemical performance fuels 60% profit jump, while Zettaone acquisition marks a bold shift into electronics.

What just happened

Jubilant Ingrevia reported significant growth for the quarter ended September 30, 2026. Consolidated revenue climbed to Rs 1,394 crore, up from Rs 1,120 crore in the same period last year. Net profit followed a similar upward trajectory, reaching Rs 111 crore compared to Rs 69 crore in Q2 FY26. Basic Earnings Per Share (EPS) rose to Rs 7.07.

Why this matters

The company’s core business segments—Speciality Chemicals, Nutrition & Health Solutions, and Chemical Intermediates—all contributed to the robust bottom-line performance. However, the most notable development is the move into the Electronics Development and Manufacturing Services (EDMS) sector. By acquiring a 40% stake in Zettaone Technologies for Rs 189 crore, Jubilant Ingrevia is diversifying away from its traditional chemical portfolio to capture value in the semiconductor and electronics ecosystem.

Risks to watch

While profitability is currently strong, investors should track the integration of Zettaone Technologies. The electronics manufacturing space has different capital expenditure cycles and competitive dynamics compared to the chemical industry. Additionally, the company maintains Rs 100 crore in outstanding commercial papers due in December 2026, which requires disciplined treasury management.

What to track next

Watch for the timeline of the Zettaone integration and any operational synergies reported in upcoming quarters. Shareholders will also monitor how the company balances its capital allocation between chemical capacity expansion and its new foray into electronics hardware.